Alzheimer's disease (AD) is the most common form of dementia and the most common neurodegenerative disease, with a complex genetic background. Genome-wide association studies (GWAS) have yielded important new insights into genetic mechanisms of AD pathology. Current results unequivocally confirm apolipoprotein E (APOE) as a major genetic risk factor for development of late onset AD. Additional associations of more than twenty genes have also been identified and replicated in subsequent genetic studies. Despite the exciting new GWAS data which have emerged in the last few years, it has become clear that common variants within the genome cannot fully explain the underlying genetic risk for AD. Novel approaches such as genome-wide analysis of copy number variations (CNV) or low-frequency rare functional gene variants may provide additional insight into genetic basis of AD. In this review we summarize the findings of eighteen GWAS studies in AD performed to date, with an emphasis on potential future developments in the quest for genetic risk factors of AD.
Introduction
Alzheimer's disease (AD) is the most common form of dementia and the most common neurodegenerative disease. The estimated prevalence of the disease in 2006 was approximately 27 million people, with the highest number of patients present in the regions of Asia and Europe (Brookmeyer et al., 2007) . The number of patients with dementia is increasing by roughly 4.5 million people annually (Ferri et al., 2005) , and is projected to reach more than 115 million by the year 2050 (Prince and Jackson, 2009).
The disease is characterized histopathologically by the accumulation of β-amyloid plaques and neurofibrillary tangles, leading to progressive neuronal and synaptic loss in the limbic and association areas of cortex and in subcortical nuclei (Selkoe, 1991; Chertkow et al., 2001; Tiraboschi et al., 2004; Takashima, 2009 ). The AD patients exhibit a plethora of symptoms related chiefly to progressive cognitive and functional decline (Waldemar et al., 2007) . The pathogenesis of AD still remains not fully elucidated, but deposition of β-amyloid (Aβ) 1-42 derived from amyloid precursor protein (APP), appears to be a key element contributing to oxidative stress, tau pathology, mitochondrial insufficiency and synaptic failure. Aβ, which is the major component of senile plaques, is cleaved from APP first by β-secretase, and then by the γ-secretase.
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